Literature DB >> 16995871

Absence of an interaction between iron and mycophenolate mofetil absorption.

Patricia Sanwald Ducray1, Ludger Banken, Marianne Gerber, Bruno Boutouyrie, Hagen Zandt.   

Abstract

AIM: To determine whether concomitant iron affects the absorption of mycophenolate mofetil.
METHODS: An open-label, single centre, randomized, crossover trial was conducted in 16 healthy males. Fasting subjects received mycophenolate mofetil alone (treatment A) or co-administered with iron (treatment B).
RESULTS: The mycophenolic acid AUC(0,24 h) for treatments A and B were 42.5 +/- 10.5 and 44.7 +/- 12.4 microg ml(-1) h, respectively. anova modelling showed the relative bioavailability of mycophenolate mofetil to be similar for the two treatments (90% confidence interval 0.92, 1.19).
CONCLUSIONS: There was no interaction between mycophenolate mofetil and iron supplements administered concomitantly to healthy fasting subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16995871      PMCID: PMC1885162          DOI: 10.1111/j.1365-2125.2005.02541.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

1.  Impairment of mycophenolate mofetil absorption by iron ion.

Authors:  M Morii; K Ueno; A Ogawa; R Kato; H Yoshimura; K Wada; H Hashimoto; M Takada; K Tanaka; T Nakatani; M Shibakawa
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

2.  Indomethacin reduces lipid peroxidation in rat brain homogenate by binding Fe2+.

Authors:  Shailendra Anoopkumar-Dukie; Barbara Lack; Kerry McPhail; Tebello Nyokong; Zaynab Lambat; Deepa Maharaj; Santy Daya
Journal:  Metab Brain Dis       Date:  2003-03       Impact factor: 3.584

3.  The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation.

Authors:  M D Hale; A J Nicholls; R E Bullingham; R Hené; A Hoitsma; J P Squifflet; W Weimar; Y Vanrenterghem; F J Van de Woude; G A Verpooten
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

Review 4.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

5.  The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial.

Authors:  David W Mudge; Bronwyn Atcheson; Paul J Taylor; Joanna M Sturtevant; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; David L Nicol; Peter I Pillans; David W Johnson
Journal:  Transplantation       Date:  2004-01-27       Impact factor: 4.939

6.  Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients.

Authors:  Matthias Lorenz; Michael Wolzt; Günter Weigel; Heidi Puttinger; Walter H Hörl; Manuela Födinger; Wolfgang Speiser; Gere Sunder-Plassmann
Journal:  Am J Kidney Dis       Date:  2004-06       Impact factor: 8.860

  6 in total
  2 in total

1.  Iron deficiency anemia and iron losses after renal transplantation.

Authors:  Sijie Zheng; Daniel W Coyne; Heidi Joist; Rebecca Schuessler; Ambyr Godboldo-Brooks; Patrick Ercole; Daniel C Brennan
Journal:  Transpl Int       Date:  2008-12-09       Impact factor: 3.782

Review 2.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.